revision cases indicates that revision surgery with current techniques neither adequately resolves existing issues nor prevents further complications. Because the number of augmentation procedures performed in the United States increases each year, 6 the number of revision cases will also likely increase. Finding reliable techniques for minimizing the risk both of recurrence and of further complications is thus increasingly important in aesthetic breast surgery.
Revision breast surgery in augmentation mammaplasty patients, however, presents particular challenges. These patients often have thinned breast tissue, inadequate local tissue, and/or a scarred breast envelope; they often present with a number of complications-typically ptosis, tissue atrophy, CC, and/or implant malposition. Revision surgery, often involving a combination of procedures (including capsule modification, pocket change, mastopexy, and implant exchange), is technically demanding. Obtaining consistent and durable results can be difficult. Moreover, when attempting to revise one complication, another complication may be created inadvertently, further compounding the problem.
In the quest to improve outcomes and minimize complications in breast revision surgery, since 2007 we have applied acellular dermal matrices (ADM) to reinforce repairs and provide additional soft tissue coverage. 7 In this article, we report our experience and long-term outcomes with breast revision surgery as performed with a noncross-linked porcine ADM, Strattice (LifeCell Corporation, Branchburg, New Jersey), in conjunction with traditional techniques. As site change is performed during revisionary procedures, efficacy of the neopectoral pocket 8, 9 combined with Strattice is also reported.
MEthodS
This study was approved by IRBNet through Peacehealth in Vancouver, Washington. All patients in our practice who undergo revision breast surgery following augmentation mammaplasty are routinely offered ADM, because additional support is needed for reinforcement. For this study, the charts of patients who underwent revision surgery between January 2007 and December 2011 were retrospectively reviewed. Specifically, patients who had undergone revision augmentation or revision augmentation/mastopexy surgery using Strattice, and who had a minimum of 12 months of follow-up, were identified and formed the analysis cohort of this study. During the study period, a total of 169 patients underwent revision augmentation or augmentation-mastopexy surgeries with the assistance of an ADM. Of these patients, 106 (62.7%) met the inclusion criteria. Data on demographics, medical comorbidities, type of initial breast surgery (augmentation or augmentationmastopexy), indications for revision surgery, number of previous revision surgeries, previous implant location (subpectoral or subglandular), and implant type used for revision were collected. The demographics of these patients are summarized in Table 1 .
The revision procedure performed depended on the particular indication for surgery, broadly categorized as CC, implant malposition, ptosis, or wrinkling/rippling. Detailed descriptions of the revision procedures performed for each indication have been previously published. 10, 11 Briefly, regardless of the indication, all revisions included some form of capsule modification such as capsulectomy, capsulotomy, and/or capsulorrhaphy with or without site change. In all patients with subglandular pockets, a plane change to subpectoral was made; in most patients with subpectoral pockets, a neosubpectoral pocket was dissected. In a minority of patients with subpectoral pockets, a dual-plane conversion was performed. In all cases, capsule access was achieved via an inframammary approach, and existing implants were replaced. Surgical wounds were irrigated with triple antibiotic solution (bacitracin 50 000 U, cephazolin 1 g, and gentamicin 80 mg in 500 mL normal saline); implants and Strattice were soaked in the triple antibiotic solution prior to insertion. Depending on the surgical indication, Strattice was placed and sutured either to reinforce the repair at the inferior, medial, or lateral poles of the pocket or to reinforce thinned soft tissue. In most cases, a 9 × 18.5-cm sheet of Strattice was applied. Drains were used in all revision procedures to minimize seroma formation, although seroma appears to be a problem primarily with human ADM, particularly in products that poorly incorporate and vascularize. Patient selection and sound surgical technique remain important in enhancing surgical outcomes. Following revision surgery, all complications (including seroma, hematoma, CC, infection, and implant loss or exposure), and any subsequent related or unrelated revision surgeries performed during the follow-up period, were recorded. The duration of follow-up for each patient was also noted.
RESuLtS
Overall, our patient cohort was relatively young, with a mean age of 42.3 years (range, 24-66 years), and had no comorbidities, with the exception of 1 patient. This patient was a current smoker and had undergone massive weight loss prior to breast surgery. Most patients (n = 64 [60.4%]) had no prior history of revision surgery. The remaining 39.6% (n = 42) of patients had 1 or more previous attempts to correct the presenting complaint. Implant location was subpectoral in 74.5% (n = 79) of patients and subglandular in 25.5% (n = 27).
As shown in Table 2 , indications for revision surgery included CC in 51.9% (n = 55), implant malposition in 38.7% (n = 41), and ptosis in 8.5% (n = 9). During revision surgery, among patients who had subpectoral implants, a neosubpectoral pocket was created in 81% (n = 64); in the remainder of patients (19%, n = 15), a dual-plane Lateral malposition 1 (0. conversion was performed after capsule modifications (Table  3) . Among all patients who had subglandular implants, a plane change from subglandular to subpectoral was performed (Table 3; 26.4%, n = 27). In the patient group with CC as an indication for surgery, a site change from subpectoral to neopectoral was performed in 65.5% (n = 36) of patients and subglandular to subpectoral in 29.1% (n = 16). All patients received gel implants: 50.9% smooth, 25.5% cohesive, and 23.6% textured implants. Patients were followed for a mean ± SD of 3.1 ± 1.3 years (range, 1-5.3 years). Among patients with ptosis, implant malposition, and CC as the presenting complaint, the mean follow-up was 2 years (range, 1.1-2.8 years), 2.9 years (range, 1.0-5.0 years), and 3.6 years (range, 1.2-5.3 years), respectively. Approximately a quarter of all patients (24.5%) had at least 2 years of follow-up, and half the patients (54.7%) had at least 3 years of follow-up.
During the follow-up period, 1 patient experienced a complication, yielding an overall complication rate of 0.9%. This patient had an infection treated with oral antibiotics. All patients' presenting complaints resolved after revision surgery, with no recurrence of the presenting complaint during the follow-up period. Before revision surgery, 48.1% (n = 52) of patients were assessed to have Baker grade 1 or 2 and 51.0% (n = 54) grade 3 or 4 CC. After revision surgery, all patients were assessed to have grade 1 or 2 CC (Table 4 ). Within the cohort of patients who had grade 3 or 4 CC before revision, 68.5% had at least 3 years, 18.5% at least 2 years, and 13% at least 1 year of follow-up after revision surgery.
Clinical results are shown in Figures 1 through 3 .
diScuSSion
Over the past decade, the rate of revision augmentation has remained relatively unchanged, 1,3,4,12 despite improvements in both implant design and augmentation procedures/techniques; this is because tissue deficit presents an underlying reason for many indications for revision surgery. Augmentation patients often have thinned breast tissue and inadequate native soft tissue. Consequently, adequate support and coverage of the breast during revision surgery-necessary for reliable, durable repair of the presenting complaint-becomes difficult to achieve. To address tissue deficit in revision breast surgery, we and others have placed ADM to reinforce repairs and provide additional soft tissue support where needed. 7, [13] [14] [15] [16] [17] In this report, we demonstrated the efficacy and safety of the ADM Strattice when used for this purpose.
Strattice is derived from porcine dermis and has been processed to remove cells as well as epitopes responsible for xenogenic rejection response. 18 When used in breast reconstruction, Strattice has been shown to regenerate and incorporate into host tissue without evidence of a rejection response. [19] [20] [21] Although the biological response of Strattice compares to human ADM, 22 its biomechanical properties are different: Strattice is firmer (ie, less elastic) and has a higher tensile strength. 23 These biomechanical properties are particularly beneficial in clinical situations where tissue support is needed-such as correction of implant malposition, CC, and ptosis-or in clinical situations when additional tissue is needed to mask implant surface irregularities, as in correction of wrinkling and rippling.
Traditionally, implant malposition has been corrected with capsular repair. In the absence of native tissue to reinforce the repair, the capsule relaxes over time, resulting in recurrence. In our series, 38.7% (n = 41) of patients had implant malposition as a presenting complaint. After revision surgery that included pocket change and reinforcement with Strattice, there was no recurrence during the follow-up period. Of note, approximately 40% (n = 17) of these patients had undergone 1 or more previous attempts to correct implant malposition, including 1 patient with 9 previous attempts ( Table 2) .
Breast ptosis, a common problem among augmentation patients, occurs because over time subglandularly or subpectorally placed implants can cause thinning, atrophy, and/or stretching of overlying soft tissues. This accelerates age-related natural changes in breast shape and volume. Revision of ptosis often involves mastopexy in conjunction with site change and implant exchange, but in the absence of sufficient lower-pole muscle coverage of the implant, ptosis may recur. In our series, ptosis was the indication for revision in about 9% (n = 9) of patients. After mastopexy with Strattice reinforcement of the lower pole, there was no recurrence in these patients.
Revision surgery for capsular contracture has traditionally included capsulotomy or capsulectomy, with or without pocket change and implant exchange. 24, 25 These techniques are not completely reliable, for they have produced unpredictable results and are less effective, especially in recurrent contracture. 15 Hester et al 16 reported a recurrence rate of 53% in augmentation patients using traditional techniques, which increased to 74% in those who had a previous recurrence. However, when they introduced Strattice in their treatment procedure to reinforce the lower-pole pocket, recurrence dropped to 6.6% during an average follow-up of 1.5 years. In our series, of the 52% (n = 55) of patients who presented with capsular contracture, none experienced recurrence during the follow-up period, which was at least 3 years in almost 70% (n = 37) and at least 2 years in approximately 20% (n = 11) of these patients. Forty percent (n = 22) of the patients had undergone more than 1 previous attempt to correct capsular contracture, including 1 patient who underwent 7 attempts (Table 2) .
Often during correction of CC there is concern about retaining the previous capsule in the neosubpectoral procedure because of the potential for recurrent contracture or other complications. In our experience, we have found the retention of noncalcified capsules to be safe. In this series, almost two-thirds (n = 36) of patients with CC had their previous noncalcified capsules retained, and these patients experienced no recurrences or other complications.
The low rate of CC with Strattice has also been observed both in patients who received Strattice during breast reconstruction 20, 21 and in primary augmentation patients who received Strattice as a prophylactic measure for CC prevention. 16 The low contracture rate associated with Strattice is not unique to Strattice but also has been previously observed with the placement of human ADM. When applied during reconstructive or revision surgery, a less than 5% rate of clinically significant CC has been reported with human ADM. 7, 15, [26] [27] [28] [29] [30] Taken together, the data suggest an intrinsic capacity of ADM (human or xenogenic) to mitigate development of CC. The exact mechanism by which ADM may mitigate risk of CC has not yet been elucidated, but it is postulated that they may provide a barrier between the implant and the host immune response, thereby minimizing capsule formation. 31 Overall, all presenting complaints were successfully resolved in this study with no evidence of recurrence over a mean follow-up period of 3 years. In addition, short-term complications associated with revision surgery were minimal. Two recent studies have similarly reported safe, effective application of Strattice in revision breast surgery, albeit during a shorter follow-up period, 17, 32 thus corroborating our results. The availability of a control group that underwent breast revision without placement of Strattice would have provided perspective on complications and recurrences after revision surgery using traditional techniques; this lack represents a limitation of our study. Nevertheless, a review of published studies concerning traditional techniques reveals a reoperation rate of 20% to 40% in patients who have undergone revision augmentation. [1] [2] [3] [4] The reliable and durable repair of presenting complaints in our study, together with the 2 recent studies, 17, 32 supports treatment with Strattice in conjunction with traditional techniques in revision breast surgery.
concLuSionS
Revision breast surgery represents a significant problem for patients who have undergone augmentation mammaplasty. Novel approaches are needed to resolve this problem, as current techniques do not adequately prevent or minimize recurrence. In this study, adding Strattice to traditional revision surgery procedures resulted in reliable and durable repair of the presenting complaint. Complications associated with this procedure were minimal. Retention of noncalcified capsules during a site change operation, in conjunction with Strattice placement, also appeared to be safe. The data support a role for Strattice in revision breast surgery in patients who have undergone previous augmentation mammaplasty.
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